Allogeneic melanoma vaccine expressing αgal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity

Journal of Immunotherapy

Volumn 31, Issue 6, 2008, Pages 545-554

  Rossi, Gabriela R ^a   Mautino, Mario R ^a   Awwad, Dana Z ^a   Husske, Katie ^a   Lejukole, Henry ^a   Koenigsfeld, Marie ^a   Ramsey, William J ^a   Vahanian, Nicholas ^a   Link, Charles J ^a  

^a NEWLINK GENETICS   (United States)

Author keywords

Gal epitope; Adjuvant; Immunotherapy; Melanoma; Xenotransplant

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ALPHA GALACTOSIDASE; AUTOANTIGEN; CANCER VACCINE; EPITOPE; GAMMA INTERFERON; MELANOMA VACCINE; TUMOR ANTIGEN; ALPHA GALACTOSYL EPITOPE; ALPHA-GALACTOSYL EPITOPE; TRISACCHARIDE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; BLOOD CELL COUNT; BLOOD CHEMISTRY; BLOOD TOXICITY; BODY WEIGHT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SIZE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; ISOGRAFT; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA; MELANOMA B16; METASTASIS INHIBITION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; WEIGHT CHANGE; ANIMAL; C57BL MOUSE; DBA MOUSE; EXPERIMENTAL MELANOMA; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; LUNG TUMOR; METASTASIS; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; SKIN NEOPLASMS; TRISACCHARIDES;

EID: 48549091423     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31817d2f45     Document Type: Article

References (33)

1. Galili U, Mandrell RE, Hamadeh RM, et al. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun. 1988;56:1730-1737.
2. Link CJ Jr, Seregina T, Atchison R, et al. Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy. Anticancer Res. 1998;18:2301-2308.
3. Schaapherder AF, Daha MR, te Bulte MT, et al. Antibodydependent cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera. Transplantation. 1994;57:1376-1382.
4. Watier H, Guillaumin JM, Vallee I, et al. Human NK cell-mediated direct and IgG-dependent cytotoxicity against xenogeneic porcine endothelial cells. Transpl Immunol. 1996;4:293-299.
5. Rossi GR, Mautino MR, Unfer RC, et al. Effective treatment of pre-existing melanoma with whole cell vaccines expressing A(1,3)- galactosyl epitopes. Cancer Res. 2005;65:10555-10561.
6. Rossi GR, Unfer RC, Seregina T, et al. Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopes. Cancer Immunol Immunother. 2005;54:999-1009.
7. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004;200:297-306.
8. Robbins PF, el-Gamil M, Kawakami Y, et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 1994;54:3124-3126.
9. Naftzger C, Takechi Y, Kohda H, et al. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA. 1996; 93:14809-14814.
10. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372-8377.
11. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
12. Overwijk WW, Lee DS, Surman DR, et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA. 1999;96: 2982-2987.
13. van Elsas A, Sutmuller RP, Hurwitz AA, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 2001;194:481-489.
14. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569-580.
15. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90: 3539-3543.
16. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194:823-832.
17. Hodge JW, Grosenbach DW, Aarts WM, et al. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res. 2003;9:1837-1849.
18. Gross DA, Graff-Dubois S, Opolon P, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest. 2004;113:425-433.
19. Mitchell MS, Abrams J, Thompson JA, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol. 2007;25:2078-2085.
20. Nemunaitis J, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 2006;13:555-562.
21. Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res. 2005;11:4469-4478.
22. Thall AD, Maly P, Lowe JB. Oocyte Gal alpha 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse. J Biol Chem. 1995; 270:21437-21440.
23. Unfer RC, Hellrung D, Link CJ Jr. Immunity to the alpha(1,3) galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy. Cancer Res. 2003;63:987-993.
24. Gorelik E, Duty L, Anaraki F, et al. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by alpha 1,3 galactosyltransferase gene transfection. Cancer Res. 1995;55:4168-4173.
25. Kim M, Rao MV, Tweardy DJ, et al. Lectin-induced apoptosis of tumour cells. Glycobiology. 1993;3:447-453.
26. Zhu Z, Sanchez-Sweatman O, Huang X, et al. Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res. 2001;61: 1707-1716.
27. Rossi GR, Mautino MR, Morgan RA. High-efficiency lentiviral vector-mediated gene transfer into murine macrophages and activated splenic B lymphocytes. Hum Gene Ther. 2003;14:385-391.
28. Spiro RG, Bhoyroo VD. Occurrence of alpha-D-galactosyl residues in the thyroglobulins from several species. Localization in the saccharide chains of the complex carbohydrate units. J Biol Chem. 1984;259:9858-9866.
29. Janjic B, Andrade P, Wang XF, et al. Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006;177:2717-2727.
30. Wang RF, Johnston SL, Zeng G, et al. A breast and melanomashared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998;161: 3598-3606.
31. Otahal P, Hutchinson SC, Mylin LM, et al. Inefficient crosspresentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. J Immunol. 2005;175:700-712.
32. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998;58:1486-1493.
33. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384.